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ABSTRACT:  
Background: Anxiety disorders are a major cause of burden of disease. Treatment gaps 
have been described, including lack of awareness and inadequate treatment, but a 
worldwide evaluation is lacking. Here we estimate, among individuals with a 12-month 
DSM-IV anxiety disorder in 21 countries, the proportion who: i) perceived a need for 
treatment; ii) received any treatment; and (iii) received possible minimally adequate 
treatment. 
Methods: Data from 24 community surveys in 21 countries of the WMH surveys. DSM-IV 
mental disorders were assessed using the WHO Composite International Diagnostic 
Interview (CIDI 3.0). DSM-IV included PTSD among anxiety disorders, while it is not 
considered so in the new DSM-5. Respondents were asked if, in the previous 12 months, 
they felt they needed professional treatment and if they obtained professional treatment 
(specialized or general medical, complementary alternative medical –CAM- or non-medical 
professional) for “problems with emotions, nerves, mental health, or use of alcohol or 
drugs”. Possible minimally adequate treatment was defined as receiving pharmacotherapy 
(1+ months of medication and 4+ visits to a medical doctor) or psychotherapy, CAM or 
non-medical care (8+ visits). 
Results: Of 51,547 respondents (response rate=71.3%), 9.8% had a 12-month DSM-IV 
anxiety disorders, 27.6% of whom received any treatment, and only 9.8% received possible 
minimally adequate treatment.  Only 41.3% of those with 12-month anxiety perceived a 
need for care.  Lower treatment levels results were found for lower income countries. 
Conclusions: Low levels of service use and a high proportion of those receiving services not 
meeting possible minimally adequacy standards for anxiety disorders exist worldwide.  
Results suggest a strong need for improving recognition of anxiety disorders and the 
quality of treatment. 
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INTRODUCTION 
Anxiety disorders are frequent (lifetime prevalence ranging between 5 and 25 % of the 
population, and a 12-month prevalence ranging between 3.3 and 20.4%, 
worldwide)(Kessler et al., 2009). When adjusted for methodological differences, current 
(3-month) prevalence is estimated at 7.3% worldwide (4.8-10.9%), ranging from 5.3% (3.5-
8.1%) in African settings to 10.4% (7.0-15.5%) in Euro/Anglo settings(Baxter, Scott, Vos, & 
Whiteford, 2013). Some anxiety disorders, in particular the phobias, social anxiety and 
separation anxiety, have very early age of onset (median ages in the range of 5-10 years of 
age(Kessler et al., 2009), while others (generalized anxiety disorder, panic disorder, and 
post-traumatic stress disorder) tend to have a later age-of-onset distributions (median 24-
50), with much wider cross-national variation.   
Because of their relatively high prevalence, their tendency towards chronicity and 
substantial comorbidity, anxiety disorders are associated with significant disability (Harter, 
Conway, & Merikangas, 2003; Saha, Stedman, Scott, & McGrath, 2013). Anxiety disorders 
cause 10.4% of the Disability Adjusted Life Years (DALYs) lost due to neurological, mental, 
substance use disorders and account for 1.1% of the global burden of disease worldwide, 
that is  a total of 26,800,000 DALYs worldwide (Whiteford, Ferrari, Degenhardt, Feigin, & 
Vos, 2015). Anxiety disorders are also very costly. It has been estimated that the total costs 
of anxiety disorders were € 74.4 billion for 30 European EU countries in 2010 (Gustavsson 
et al., 2011). 
Cognitive-behavioral therapy (CBT) and selective serotonin reuptake inhibitors 
(SSRIs) are effective  treatments for anxiety disorders (Hoffman & Smits, 2008; Koen & 
Stein, 2011). Therefore anxiety disorders are among the conditions that have been 
identified by the WHO for scaling up interventions for mental disorders (WHO, 2017; 
Chisholm et al., 2016). Yet a number of barriers limit the effective treatment of anxiety 
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disorders.  First, they are often unrecognized.  Recognition rates in primary care may be 
lower than 50% (Culpepper, 2003).  Using standardized case detection methods has been 
recommended to improve their recognition in primary settings (Culpepper, 2003; Olariu et 
al., 2015).  Structural and health system weaknesses, including scarce mental health and 
human services (World Health Organization, 2010) as well as lack of awareness and costs 
of treatment (Ho, Hunt, & Li, 2008) and stigma perceived by the people who experience  
anxiety disorders, further limit their treatment (Clement et al., 2015).  
All these factors result in a low use of health services for anxiety disorders. Even in 
high income countries, only about a third of individuals with anxiety disorders receive any 
treatment (Alonso et al., 2004; Hamalainen, Isometsa, Sihvo, & Pirkola, 2008), with the 
exception of the United States, where treatment rates are considerably higher (Olson, 
Marcus, Wan, & Geissler, 2004). Importantly, the proportion of patients with anxiety 
disorders who receive adequate treatment is still much lower (Roberge et al., 2015; 
Kasteenpohja et al., 2016), even in the US, with less than 15% of people with diagnosed 
anxiety receiving treatment which conforms with evidence-based recommendations 
(Roberge et al., 2015; Kasteenpohja et al., 2016). The treatment gap for anxiety seems to 
be even wider in low and middle income (LMIC) countries (Gureje et al., 2008), which is 
consistent with reports for major depressive disorders (MDD) (Thornicroft et al., 2017), 
and for overall mental disorders (Wang et al., 2007a). In addition, little is known about the 
access to treatment for anxiety disorders and its adequacy in Low and Middle Income 
countries (LMICs). Also different studies have used different definitions of adequate 
treatment. For possible minimally adequate pharmacotherapy, any or all of the following 
criteria have been considered: type, dosage, duration, plus the number of consultations.  
For minimally adequate psychotherapy, the number of sessions (either 8 or 12) and 
sometimes, the type of therapy (i.e., cognitive behavioral treatment by the same mental 
health professional) have been proposed (Roberge et al., 2015). 
12 
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The WMH surveys, including information on anxiety disorders and related 
treatment across 21 diverse countries worldwide, provide an unprecedented opportunity 
to examine receipt of treatment for anxiety disorders. On one hand, countries from the 
whole spectrum of income and geographical variation have been included. On the other, 
common assessment methods and definitions have been used.  The specific objectives of 
this study were to estimate, among individuals with a 12-month DSM-IV anxiety disorder: i) 
the proportion who perceived a need for treatment; ii) the proportion of those who 
received any treatment; and (iii) the proportion who received possible minimally adequate 
treatment. We also examined the influence of comorbidity on perceived need for 
treatment and whether the latter varied across countries.  
It is important to note that in the current Diagnostic Statistical Manual (DSM5) 
post-traumatic stress disorder (PTSD) is no longer considered an anxiety disorder (as it was 
in the previous version, the DSM-IV). PTSD is currently considered a different type of 
disorder and it t has been moved to a separate chapter (Trauma and Stress-Related 
Disorders, DSM-5.) (American Psychiatric Association, 2013).  The reader should be aware 
that the WMH surveys used the DSM-IV classification and therefore we included PTSD 
among anxiety disorders. 
METHODS 
Sample 
Data came from 24 community epidemiological surveys administered in 21 
countries as part of the WMH surveys (Kessler & Ustun, 2004).  These included 12 surveys 
carried out in high-income countries, 6 surveys in upper-middle-income countries and 6 in 
low or lower-middle income countries (see table 1). The majority of surveys were based on 
nationally representative household samples. Three were representative of urban areas in 
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their countries (Colombia, Mexico, and Peru). Three were representative of selected 
regions in their countries (Japan, Nigeria, and Murcia, Spain). Four were representative of 
selected Metropolitan Areas (Sao Paulo, Brazil; Medellin, Colombia; and Beijing-Shanghai 
and Shenzhen in the People’s Republic of China (PRC)). Trained lay interviewers conducted 
face-to-face interviews with respondents, aged 18 years and over. The interviews took 
place within the households of the respondents. To reduce respondent burden, the 
interview was divided into two parts. Part I assessed core mental disorders and was 
administered to all respondents. Part II, which assessed additional disorders and 
correlates, was administered to all Part I respondents who met lifetime criteria for any 
disorder plus a probability subsample of other Part I respondents. Part II data, the focus of 
this report, were weighted by the inverse of their probabilities of selection into Part II and 
additionally weighted to adjust samples to match population distributions on the cross-
classification of key socio-demographic and geographic variables. Further details about 
WMH sampling and weighting are available elsewhere(Heeringa et al., 2008).  Response 
rates ranged between 45.9% and 97.2% and had a weighted average of 70.1% across all 
surveys.  
Measures 
Mental disorders 
Mental disorders were assessed using the WHO Composite International 
Diagnostic Interview (CIDI) Version 3.0, a fully-structured interview generating lifetime and 
12-month prevalence estimates. Disorders considered in this paper are based on the DSM-
IV and include: 12-month anxiety (agoraphobia; generalized anxiety disorder; panic 
disorder; post-traumatic stress disorder; social phobia; specific phobia; adult separation 
anxiety disorder).  It is important to note that in the latest Diagnostic Statistical Manual 
(DSM5) post-traumatic stress disorder is no longer considered an anxiety disorder. It is 
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considered a different type of disorder and it t has been moved to a separate chapter 
(Trauma and Stress-Related Disorders, DSM-5.) (American Psychiatric Association, 2013).  
The reader should be aware that we used the DSM-IV classification in this paper and PTSD 
is included among the anxiety disorders analyzed here. 
The WMH CIDI interview translation, back-translation, and harmonization protocol 
required culturally competent bilingual clinicians to review, modify, and approve key 
phrases describing symptoms (Harkness et al., 2008).  Blinded clinical reappraisal 
interviews with the Structured Clinical Interview for DSM-IV (First, Spitzer, Gibbon, & 
Williams, 2002) were carried out in four countries. Good concordance was found with 
diagnoses based on the CIDI (Haro et al., 2006).  
12-Month Mental Health Service Use 
Within disorder-specific sections of the survey, respondents were asked whether or not they ever 
talked to a medical doctor or other professional (including psychologists, counselors, spiritual 
advisors, herbalists, acupuncturists, and other healing professionals), and if they ever have, they 
were asked if they received treatment in the last 12 months. Additionally, in the services section of 
the survey, respondents were asked if they ever in their lifetime went to see any professional on a 
provided list for problems with emotions, nerves, or use of alcohol or drugs. This list included 
psychiatrists, general practitioners or family doctors, any other medical doctors, psychologists, social 
workers, counselors, any other mental health professionals (such as psychotherapists or mental 
health nurses), nurses, occupational therapists, or other health professionals, religious or spiritual 
advisors, or any other healers (like herbalists, chiropractors, or spiritualists). If the respondent 
reported ever seeing a given professional from the list, he or she was further probed if the given 
professional was seen in the past 12 months, and how many visits occurred in the past 12 months. In 
addition, respondents were asked about the number of self-help groups they attended in the past 12 
months. 
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Those having responded “yes” to seeing a professional or attending a self-help group in the 
past 12 months in either the disorder-specific survey section or the services section were considered 
having received any 12-month treatment. Any treatment in the past 12 months was further 
classified as (1) specialist mental health treatment (psychiatrist, psychologist, other mental health 
professional in any setting, social worker or counselor in a mental health specialist treatment 
setting, used a mental health hotline); (2) general medical treatment (primary care doctor, or other 
medical doctor, or other healthcare professional seen in a general medical setting); (3) 
complimentary alternative medicine (CAM) (any other type of healer such as chiropractors or 
participation in self-help groups); or (4) non-medical treatment provider (religious or spiritual 
advisor, social worker, or counsellor in any setting other than specialist mental health) for a mental 
health problem.   
The above classification follows the logic of hierarchy of efficacy of treatments 
from the most medically specialized, general medical, complementary and alternative 
medicine and non-medical.  It is important to note that social workers or counselors in the 
non-medical treatment group only refer to those working outside of the health services 
settings.  Those working in a specialized or a primary care setting were included in their 
respective categories (specialized or primary care). 
We also asked participants to report whether they felt they needed professional 
treatment for their mental health problems.  Those responding yes and those reporting 
using mental health services in the previous 12-month were considered to perceive a need 
for health care.  
Socio-economic characteristics 
To assess educational attainment, respondents were asked how many years of education 
they completed. As educational levels and systems varied across countries, responses were 
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divided into four groups based on country-specific distributions. Annual family income was 
classified into quartiles as related to within-country median values of income per family 
member before taxes.  
Analysis  
The analyses reported here focus on respondents who met DSM-IV criteria for any anxiety 
disorder at some time in the 12 months before interview. The definition used for possible 
minimally adequate treatment was that of Wang et al (Wang et al., 2007a), and Thornicroft 
et al (Thornicroft et al., 2017), and was based on evidence-based guidelines(Agency for 
Health Care Policy and Research (AHCPR), 1993; Lehman & Steinwachs, 1998; American 
Psychiatric Association, 2006) that consisted of receiving either pharmacotherapy (the 
respondent had to report having taken medication for at least 1 month as well as having 
been visited by a medical doctor at least 4 times, both in the previous 12 months for their 
mental health problems. We assume that supervision and control of medication is required 
and for that reason we still consider this pharmacotherapy treatment) or psychotherapy or 
complementary alternative medicine (reporting 8+ visits with any professional including 
religious or spiritual advisor, social worker or counselor). Our decision to use four or more 
physician visits alongside pharmacotherapy was based on the fact that for medication 
assessment, initiation and monitoring, four or more visits are generally recommended 
during the acute and continuation phases of treatment. We required at least eight sessions 
for psychotherapy based on the fact that clinical trials showing efficacy have generally 
included eight or more visits. Because adequacy definitions used in our study did not 
distinguish between CAM and non-medical sector, our analyses combine these two 
categories.  
We considered visits to all sectors for the analysis of possible minimally adequate 
treatment, since small numbers preclude categorization by service sector. 
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Statistical analyses 
Survey sampling weights were applied in all analyses so that respondents reflected 
nationally representative samples in terms of sociodemographic characteristics within 
each country. Standard errors were estimated using the Taylor series linearization method 
implemented in the SAS software survey procedures to adjust weighting and clustering. To 
test for differences between high-income, upper-middle-income, and lower-middle- and 
low-income country groups, in relation to the key variables of interest related to the aims 
of the paper, chi-square tests were applied. Statistical significance was evaluated using 
two-sided 0.05-level tests. 
 
RESULTS 
The characteristics of the study sample and survey response rates are presented in Table 1.  
In total, 17 nationally representative surveys and 6 large regionally representative samples 
were analyzed, with a total of 51,547 Part II respondents (12,285 from low, 12,598 from 
middle-upper, and 26,664 from high income countries). The overall weighted response 
rate was 71.3%. 
--- Table 1, about here --- 
As shown in Table 2 (first column), a total of 9.8% of respondents met criteria for at least 
one anxiety disorder in the 12 months prior to the interview. Prevalence figures were 
similar for high-income (10.3%) and upper-middle income (10.6%) countries, but lower for 
low-/lower-middle-income countries (7.9%).  The United States (19.0%) and the 
metropolitan area of Sao Paulo (18.0%) were the sites with the highest prevalence, while 
Beijing/Shanghai (3.0%), Israel (3.6%), Nigeria (4.2%) and Japan (4.5%) had the lowest 
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prevalence (Table 2, first column).  A full account of the prevalence of anxiety disorders in 
the World Mental Health surveys may be found in previous publications (Demyttenaere et 
al., 2004; Kessler & Ustun, 2008) . 
Because our study was based on a community dwelling population, we could 
estimate the proportion of all the individuals meeting DSM-IV diagnostic criteria for any 
anxiety disorders in the overall population who received any treatment (Table 2, column 
2).  This was just over a quarter (27.6%, ranging from 36.3% in high income countries to 
13.1% in low/middle-income countries). The proportion of respondents with an anxiety 
disorder who received possible minimally adequate treatment was as low as 9.8% (ranging 
from 13.8% in high-income to 2.3% in low/middle income countries) (Table 2, column 3).   
On average, less than half (41.3%) of the individuals with anxiety disorders 
reported a need for treatment (Table 2, column 4).  Self-perception of need for treatment 
was higher in high-income countries (48%) with a clear gradient across country types, with 
a minimum of 28.5% in lower-middle income countries. Two thirds (66.8%) of individuals 
with an anxiety disorder who perceived a need for care received any treatment in the 
previous year (Table 2, column 5). This proportion showed a negative gradient by country 
income: 75.0% used services in high-income countries vs 46.1% in lower-middle-income 
countries.  Perception of need for treatment was highest in Israel, the US and Peru, while 
participants in Nigeria, Iraq and Lebanon had the lowest perception of need.  In Nigeria, 
the region of Murcia in Spain and Italy more than 90% of those who perceived a need for 
care received some treatment , while others show low access (Lebanon, Colombia, Peru or 
Mexico).  
--- Table 2, about here --- 
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Table 3 presents similar data to those in  table 2, but stratified by two groups: (1) 
individuals with anxiety disorders without other comorbid mental disorders (Table 3, 
upper section) and (2) those with an anxiety disorder who also had a comorbid anxiety 
disorders (Table 3, lower section).  Among those without comorbidity, perception of need 
for treatment was lower among those without comorbidity (overall, 26.3 vs 55.2%, 
p<.001), Service use among those with a perception of need, however, was similar among 
those without and those with mental comorbidity (62.7% and 68.6%, respectively). Among 
individuals who perceived a need for help, the proportion receiving possible minimally 
adequate treatment  varied among those without comorbidity and those with comorbidity 
(20.5% and 34.5%, respectively, p<.001).These trends are present in all country income 
level groups.  
--- Table 3, about here --- 
Statistical analysis results for Tables 2 and 3 are presented in Supplementary Tables s1 and 
s2.  Comparisons across all country surveys and comparisons across the 3 income groups 
were all significant in both tables.  Tests for differences within high income levels were all 
significant for all analyses.  Results for within group comparisons of other country income 
groups were also significant, with the exception of within group comparisons of 
lower/lower-middle income countries for any treatment (column 2, table s1); and for the 
same comparison within upper-middle income countries for possible minimally adequate 
treatment among those perceiving need of treatment (column 3, table s1). Supplementary 
table s2 indicated that the vast majority of differences between pure and comorbid anxiety 
indicators are statistically significant, with exceptions confined to four cells with low 
numbers of observations. 
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DISCUSSION 
A major finding of this study is that across 21 countries worldwide, only about a fourth 
(27.6%) of individuals meeting criteria of a DSM-IV anxiety disorder have received any 
treatment in the previous year.  One important determinant of this treatment gap is that 
individuals do not perceive a need for treatment (less than half of individuals with a 12-
month anxiety disorder reported a need for treatment).  But other barriers may also exist, 
as only about two thirds of those who perceived a need for treatment actually received it.  
A second major finding is that the quality of treatment received by individuals with anxiety 
disorders seems suboptimal, since only about a third of treated cases met the criteria for 
our definition of possible minimally adequate treatment.  Thus, fewer than 1 in 10 
individuals with anxiety disorders received possible minimally adequate treatment in a 
given year.  The treatment gap was much wider for less wealthy countries.  Having a 
comorbid mental disorders was associated with an increased perception of need for care, 
and a higher likelihood of receiving possible minimally adequate treatment. Our results are 
consistent with previous studies in primary care settings (Thornicroft et al., 2017), and with 
reports of undertreatment of depression disorders (Thornicroft et al., 2017) and common 
mental disorders in general (Thornicroft et al., 2017). The findings provide a global 
perspective on the treatment gap for anxiety disorders and indicate a need to improve 
access to care in all countries, in particular in low/middle income countries.  
These results must be considered in the light of several study limitations.  First, 
diagnoses of anxiety disorders were based on the CIDI 3.0. Although acceptable agreement 
between CIDI diagnoses and diagnoses made during blind clinical re-interviews (Haro et al., 
2006) was achieved, these studies were conducted almost exclusively in high income 
countries.  It remains possible that the accuracy of CIDI anxiety diagnoses could vary in 
lower income countries. Second we used the DSM-IV classification which considered post-
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traumatic stress disorder an anxiety disorder.  But DSM-5 considers PTSD a different type 
of disorder (American Psychiatric Association, 2013). There is a need to further evaluate 
the anxiety treatment gap using DSM-5 criteria.  Third, we relied on self-reported data for 
use of services, and we were not able to corroborate responses with administrative 
records.  Accuracy of self-reported use of services may differ across sociodemographic and 
cultural groups and this might affect the comparisons across countries (Luck, 1996; Mann 
et al., 1992). Nevertheless, a number of survey methods attempted to augment recall and 
accurate responses, including survey commitment probes and exclusion of individuals 
failing to endorse commitment. Fourth, we considered those reporting using services “for 
problems with emotions, nerves, mental health or use of alcohol of drugs” as receiving 
treatment.  It may well be that the treatment received was not addressing their anxiety 
disorder. This might have led us to underestimate the treatment gap for anxiety disorders. 
On the other hand, patients might not recognize or consider themselves as having 
“problems with emotions, nerves, mental health, or use of alcohol or drugs” and yet they 
could still be treated with psychotropic medication for their somatic symptoms and/or 
sleep issues. This bias would lead us to overestimate the level of treatment gap for anxiety 
disorders.  
Additionally, we did not consider severity of anxiety disorder, which could have 
allowed to estimate whether international differences in use of adequacy are related to 
variation in severity of anxiety disorders.  We also used a broad definition of possible 
minimally adequate treatment.  On one hand, this definition did not include specific 
effective psychotherapeutic techniques, such as mindfulness meditation (Vollestad, 
Nielsen, & Nielsen, 2012), which could have led to an underestimation of adequacy.  In 
fact, it is difficult to determine the adequacy of complementary alternative medicine 
simply by the number of sessions. And, in relation to pharmacotherapy, we did not 
consider the type of medication.  On the other hand, adequacy of benzodiazepines for 
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treatment for anxiety disorders has been questioned (Baldwin et al., 2014).  Not having 
excluded them might have led us to overestimate the adequacy of pharmacological 
treatment.  However, even with this inclusion our estimated coverage rates are rather low. 
Another limitation is that we evaluated service use over a one-year period.  This might 
underestimate utilization of services in the longer run, as there is some evidence that 
individuals with persistent symptoms of common mental disorders tend to use services if 
followed for a longer period than one year (Baldwin et al., 2014). Also, even though the 
WMH surveys included a large number of respondents, for some specific sub-analyses, the 
number of respondents included for some countries was small, rendering results less 
stable and reliable.  In addition, a more detailed analysis about use of psychopharmacology 
and psychotherapy treatments was not possible due to limitations in the way information 
was collected.  
Finally, while results show that a significant proportion of individuals with anxiety 
disorders do not perceive a need for treatment, our analyses do not allow us to draw 
conclusions about the specific barriers that may be contributing to the treatment gap for 
anxiety disorders.  A number of different barriers (i.e., stigma, logistical, among others) 
have been described (Gulliver, Griffiths, & Christensen, 2012) in the literature. We have 
not have analyzed them and we consider it very important to gather additional 
information to understand the role that different types of barriers to mental health 
treatment play in the anxiety treatment gap.   
Notwithstanding these limitations, an important treatment gap for anxiety 
disorders has been identified.  This finding is consistent with previous studies, and it 
suggests that the treatment gap for anxiety disorders is even higher than that described 
for MDD (Thornicroft et al., 2017). A lower proportion of individuals with anxiety disorders 
perceive a need for treatment (41.3% in our study) when compared to those with 
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depression (56.7% in Thornicroft et al. study).  Also, the proportion of those who receive 
treatment is lower among individuals with anxiety disorders than among those with 
depression.  And the average delay between onset of the disorder and seeking treatment 
is much longer for anxiety disorders than for MDD (Wang et al., 2007b). Finally, the 
proportion receiving possible minimally adequate treatment is also lower for those with 
anxiety disorders (9.8%) and considerably lower than for those with MDD (16.5%) 
(Thornicroft et al., 2017). Differences in the severity of symptoms may contribute to 
differences in utilization rates.  In our study, mental disorder comorbidity shows an 
important association with perception of need for care. This is likely due to a higher 
severity of symptoms among persons with comorbid anxiety (Saris, Aghajani, van der 
Werff, van der Wee, & Penninx, 2017).  There is also the possibility that some symptoms 
are not recognized as a mental disorder, but rather are attributed to somatic illnesses. This 
might be an issue for the cross-cultural validity of some diagnoses, as has been pointed out 
for PTSD (Hinton & Lewis-Fernandez, 2011). There is a need to research the factors and 
mechanisms shaping perception of need for services. 
In addition to lack of perceived need for treatment, other barriers may also play an 
important role.  Low recognition rates for anxiety disorders have been described at the 
primary care level (Olariu et al., 2015). Also, the low level of perceived need for care 
among individuals with anxiety disorders may be due to low levels of mental health 
literacy (Wang et al., 2007b; Ho et al., 2008). Efforts in both areas (i.e., increasing 
detection rates in primary care and in awareness of the potential benefits of existing 
therapies among the public) are needed.   
A worrying finding of our study is the low proportion of possible minimally 
adequate treatment for anxiety disorders.  Our data indicate that this may result from a 
combination of the generally low levels of perception of need for care, together with 
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varying level of access to care as well as differences in the quality of care provided. In this 
respect, there are potentially important opportunities for improvement in several areas. 
Health literacy and awareness should be promoted in countries with low perception of 
need, mostly among the low/lower middle income countries.  At the same time, the 
quality of treatment showed remarkable variation between and within country income 
levels.  While the assessment of possible minimally adequate treatment in our study was 
based on self-report and these may differ from information gathered from administrative 
records in health services settings, our results suggest that it is important to encourage 
health providers to follow the clinical guidelines to improve treatment quality for anxiety 
disorders.  
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